MicroPharm is pleased to announce that Flynn Pharma (Holdings) Ltd has acquired a majority shareholding in the Company.

Flynn Pharma is a specialist pharmaceutical company focused on acquiring and commercialising branded products in secondary healthcare markets.  Flynn Pharma is headquartered in Stevenage, UK.  It has sales and marketing operations in the United Kingdom, Ireland and Germany and has associates and partners in other territories.

Ebola Research

Flynn’s initial investment last year enabled MicroPharm to enter into collaboration with Public Health England and the University of Oxford for the fast-track development of a treatment for Ebola Virus Disease.  This development programme is ongoing.

C. difficile

Flynn has provided further significant funds and resources for the commercialisation of MicroPharm’s products and support expansion of their development pipeline, which currently includes products for systemic and oral administration of polyclonal antibodies to C. difficile toxins, a joint development with Public Health England and the University of Leeds.

Other therapeutic antibodies

MicroPharm has a number of other important initiatives on a range of therapeutic antibodies including snake antivenoms and drug poisoning treatments.

Investment in Product Pipeline

David Fakes, CEO of Flynn, said, “MicroPharm has an impressive, proven technology platform, which we believe has potential application in a number of emergency situations in both large and small, underserved patient populations. We at Flynn are proud to continue our investment into MicroPharm to help realise its potential”.

CEO of MicroPharm, Ian Cameron, said, “Flynn has been an important commercial partner to MicroPharm for some time.  Their investments have enabled us to move forward quickly on a number of important development projects”.

Notes to editors:

For further information/media enquiries, contact:

MicroPharm – enquiries@micropharm.co.uk

Flynn Pharma – office2@flynnpharma.com

Useful links: